{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:43:29Z","timestamp":1771663409967,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40121-021-00401-1","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T06:03:07Z","timestamp":1611381787000},"page":"605-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection"],"prefix":"10.1007","volume":"10","author":[{"given":"Ashley","family":"Barlow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily L.","family":"Heil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-604X","authenticated-orcid":false,"given":"Kimberly C.","family":"Claeys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,23]]},"reference":[{"issue":"3","key":"401_CR1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55. https:\/\/doi.org\/10.1093\/cid\/ciq146.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"401_CR2","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1128\/AAC.00227-16","volume":"60","author":"KC Claeys","year":"2016","unstructured":"Claeys KC, Zasowski EJ, Casapao AM, et al. Daptomycin improves outcomes regardless of vancomycin MIC in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2016;60(10):5841\u20138. https:\/\/doi.org\/10.1128\/AAC.00227-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"401_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clinthera.2015.09.017","volume":"38","author":"PA Moise","year":"2016","unstructured":"Moise PA, Culshaw DL, Wong-Beringer A, et al. Comparative effectiveness of vancomycin versus daptomycin for MRSA bacteremia with vancomycin MIC >1 mg\/L: a multicenter evaluation. Clin Ther. 2016;38(1):16\u201330. https:\/\/doi.org\/10.1016\/j.clinthera.2015.09.017.","journal-title":"Clin Ther"},{"issue":"1","key":"401_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/cid\/cir764","volume":"54","author":"CL Moore","year":"2012","unstructured":"Moore CL, Osaki-Kiyan P, Haque NZ, Perri MB, Donabedian S, Zervos MJ. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis. 2012;54(1):51\u20138. https:\/\/doi.org\/10.1093\/cid\/cir764.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"401_CR5","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/cid\/cit112","volume":"56","author":"KP Murray","year":"2013","unstructured":"Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >\u00a01 mg\/L: a matched cohort study. Clin Infect Dis. 2013;56(11):1562\u20139. https:\/\/doi.org\/10.1093\/cid\/cit112.","journal-title":"Clin Infect Dis"},{"key":"401_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","volume":"57","author":"S Arshad","year":"2017","unstructured":"Arshad S, Huang V, Hartman P, Perri MB, Moreno D, Zervos MJ. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study. Int J Infect Dis. 2017;57:27\u201331. https:\/\/doi.org\/10.1016\/j.ijid.2017.01.019.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"401_CR7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/cid\/civ495","volume":"61","author":"SR Evans","year":"2015","unstructured":"Evans SR, Rubin D, Follmann D, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis. 2015;61(5):800\u20136. https:\/\/doi.org\/10.1093\/cid\/civ495.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"401_CR8","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/cid\/ciy766","volume":"68","author":"SB Doernberg","year":"2019","unstructured":"Doernberg SB, Tran TTT, Tong SYC, et al. Good studies evaluate the disease while great studies evaluate the patient: development and application of a desirability of outcome ranking endpoint for Staphylococcus aureus bloodstream infection. Clin Infect Dis. 2019;68(10):1691\u20138. https:\/\/doi.org\/10.1093\/cid\/ciy766.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"401_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1080\/19466315.2016.1207561","volume":"8","author":"SR Evans","year":"2016","unstructured":"Evans SR, Follmann D. Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation. Stat Biopharm Res. 2016;8(4):386\u201393. https:\/\/doi.org\/10.1080\/19466315.2016.1207561.","journal-title":"Stat Biopharm Res"},{"key":"401_CR10","unstructured":"ANI Pharmaceuticals. Vancomycin hydrochloride product description.. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/060180s047lbl.pdf. Accessed 27 May 2020."},{"key":"401_CR11","unstructured":"Merck. Highlights of prescribing information: CUBICIN\u00ae\n(daptomycin for injection). https:\/\/www.merck.com\/product\/usa\/pi_circulars\/c\/cubicin\/cubicin_pi.pdf. Accessed 27 May 2020."},{"key":"401_CR12","unstructured":"Forest Laboratories. Highlights of prescribing information: Teflaro\u2122 (ceftaroline fosamil). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/200327s001lbl.pdf. Accessed 27 May 2020."},{"issue":"1","key":"401_CR13","first-page":"22","volume":"32","author":"J Barber\u00e1n","year":"2019","unstructured":"Barber\u00e1n J, Mensa J, Artero A, et al. Factors associated with development of nephrotoxicity in patients treated with vancomycin versus daptomycin for severe gram-positive infections: a practice-based study. Rev Esp Quimioter. 2019;32(1):22\u201330.","journal-title":"Rev Esp Quimioter"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00401-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40121-021-00401-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00401-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T06:44:25Z","timestamp":1615531465000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-021-00401-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,23]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00401-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,23]]},"assertion":[{"value":"7 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}